SpectraCell International Limited (SIL) is the international subsidiary of the SpectraCell Group responsible for operations and market development across the Asia-Pacific region. Serving China, Japan, Singapore, Thailand, South Korea, and other APAC markets, SIL provides localized testing services and commercial partnership support for physicians, medical institutions, and health management organizations. SIL maintains offices in key regional hubs such as Hong Kong and Shanghai and has established a broad network of partner physicians and blood collection sites across the region, enabling patients to complete sample collection locally while receiving continuous professional support.
SIL is backed by its parent company, SpectraCell Laboratories (SCL) — a globally recognized clinical laboratory headquartered in Houston, Texas, with over 30 years of scientific and clinical leadership. SCL is CLIA-certified for high-complexity testing and is the pioneer of live-cell functional analysis. It is a global leader in immune function, cellular nutrition, cardiovascular risk, lipoprotein metabolism, and aging-related diagnostics.
Leveraging SIL’s strategic presence in Asia-Pacific and SCL’s world-leading expertise in life sciences and precision diagnostics, SpectraCell is bringing the most advanced cell-based functional medicine into the APAC market. Together with regional physicians and healthcare institutions, we are building the next generation of precision health systems—driving the transformation from experience-based medicine to data-driven, personalized, and preventive healthcare, and delivering a healthier, longer, and more sustainable future for hundreds of millions of people across the region.